The highly sensitive nervous system — when the world is louder than you can manage

What usually doesn't happen is someone explaining the biology of it.

The trait of sensory processing sensitivity — the formal term for what the popular literature calls being a "highly sensitive person" — has a real neurobiological basis that predates and outlasts any particular life circumstance. Elaine Aron's research, beginning in the 1990s and substantially expanded since, identified sensory processing sensitivity as a genetically influenced trait present in roughly 15-20% of the population. Crucially, it appears across many species, which suggests it's not a defect but an evolutionary variation — a nervous system that's processing more information per unit time, registering subtler environmental signals, and responding with greater depth to stimuli that others filter out more aggressively. This is not pathology. But it does mean your nervous system is working differently, and that difference has real physiological mechanisms underneath it.

The core of it is heightened limbic reactivity combined with a more active orienting response. The amygdala — the brain's primary threat-detection and emotional-salience processor — appears to respond more strongly to stimuli that others register as neutral or minimal. The sensory cortices process with more depth and differentiation, which is the mechanism behind the richer inner experience, the noticing of subtlety, the strong aesthetic responses. The autonomic nervous system activates more readily. None of this is psychological hypersensitivity or maladaptive cognition. It is the system's actual architecture.

What makes the clinical picture complicated is that sensory processing sensitivity exists on a continuum, it can be exacerbated by other conditions, and several other conditions produce sensory sensitivity that gets conflated with or layered on top of the underlying trait. Sorting these out matters because the mechanisms differ and so do the interventions.

Mast cell activation syndrome — MCAS — is one of the more important ones to know about. Mast cells are immune cells distributed throughout the body, concentrated in connective tissue, skin, and mucosal surfaces, and they're involved in the inflammatory response. In MCAS, mast cells degranulate — release their inflammatory contents — in response to a wide range of triggers that a normal mast cell population would ignore: certain foods, chemical exposures, fragrance, temperature changes, vibration, sometimes emotional stress. The result is a pattern of systemic reactivity that produces symptoms across multiple organ systems: skin flushing, hives, GI distress, headaches, brain fog, sometimes anaphylaxis. For someone with high sensory processing sensitivity who also has MCAS, the combination produces a level of environmental reactivity that can be severely limiting. The mast cell component is a distinct, treatable medical condition. It often goes undiagnosed for years because the symptom picture is so diffuse that it doesn't fit a clean diagnostic box, and because many clinicians aren't familiar with it.

Autonomic nervous system dysfunction is another piece. The autonomic system — sympathetic and parasympathetic branches — regulates moment-to-moment physiological responses to stimuli, including sensory ones. Dysautonomia, which covers a spectrum of autonomic dysfunction conditions, can produce heightened sensory processing as one feature: the system that normally filters and habituates to sensory input is dysregulated, so inputs that should be processed and discarded continue to register as intrusive. This can occur in isolation or following illness, particularly viral illness. The post-COVID emergence of new or dramatically worsened sensory sensitivity is real and documented — a pattern that many people are experiencing without a framework for understanding what happened to their nervous system.

Perimenopause is a frequently missed contributor to worsening sensory sensitivity in midlife women. Estrogen has modulatory effects throughout the nervous system, including on mast cell activity — estrogen can actually upregulate mast cell degranulation, which is one reason why hormonally sensitive women with MCAS-like presentations often find symptoms worsening in the perimenopausal transition. The autonomic instability that characterizes perimenopause — the hot flashes, the palpitations, the sudden vasomotor changes — is itself a form of heightened autonomic reactivity. A woman who has always been somewhat sensitive may find the sensitivity becomes unmanageable in her mid-40s not because something new is wrong but because a hormonal shift has removed regulatory buffers that were partially compensating.

ADHD is worth naming here because sensory processing differences are a recognized feature of the ADHD nervous system, often underemphasized relative to the attention and impulsivity profile that gets more clinical attention. The rejection sensitive dysphoria that many people with ADHD describe — the intense emotional reaction to perceived criticism — is a form of heightened processing that's related to the same underlying neurological differences. If sensory sensitivity is part of a broader ADHD presentation, the approaches that address ADHD may reach the sensory piece as well.

The cultural frame of the "highly sensitive person" has become large enough that it carries some baggage. The concept is genuinely grounded — Aron's research is serious work, the trait is real, the neurobiological evidence supports it. But the popularization has sometimes drifted into a framing that treats the trait as purely identity-level rather than biological, or that romanticizes the difficulties without engaging with the mechanisms. This matters because someone whose sensory sensitivity is partly driven by MCAS, or by autonomic dysfunction, or by a mast cell component exacerbated by perimenopausal hormonal changes, needs a different conversation than someone whose baseline sensitivity is high but whose physiological systems are otherwise intact. Both are real. They require different things.

Where peptide research is entering the conversation is as adjunctive support for some of the underlying mechanisms, not as a treatment for sensitivity itself. Selank — the synthetic heptapeptide derived from tuftsin — has been researched for its potential effects on autonomic regulation and anxiety, which is relevant if the autonomic component is prominent. The proposed mechanism involves GABA modulation and a dampening of the hyperactivated stress-response baseline that many highly sensitive people carry; the evidence is early and primarily from Russian research institutions, but the mechanistic logic connects to the autonomic piece. For MCAS components, KPV and VIP (vasoactive intestinal peptide) are being researched in the context of mast cell modulation and anti-inflammatory signaling; VIP in particular has documented mast cell-stabilizing effects and is being explored in clinical contexts where mast cell dysregulation is central to the picture. Thymosin Alpha-1 enters the conversation if the immune dysregulation piece is prominent, as a compound that has been researched for its role in immune modulation and has some research interest in inflammatory and autoimmune contexts. All of these are adjunctive tools within a broader clinical protocol, not solutions to the trait itself, and the conversation about whether any of them belong in your picture is one for a prescribing provider who understands the full presentation.

The foundational interventions are often environmental and structural before they are biochemical. Environmental control — managing sensory load, building adequate recovery time after high-input situations, designing the physical environment to reduce unnecessary intrusion — is not accommodation of weakness. It's appropriate management of a nervous system architecture that has different tolerances. Recovery practices that actually restore — not just rest, but active parasympathetic recovery through the specific practices that move the autonomic baseline — are often more valuable than anything at the compounding pharmacy. Therapy that helps someone relate to their sensitivity without shame, that distinguishes between the trait's strengths and its costs, that builds practical strategies for navigating a world calibrated for a less sensitive nervous system, has a real place in this picture. None of this is about changing who you are. It's about understanding the biology well enough to stop fighting it and start managing it intelligently.

What high sensitivity is actually signaling, at the biological level, is a nervous system with a low sensory threshold, a high-gain processing style, and an autonomic system that activates readily and doesn't always return to baseline as quickly as a lower-sensitivity system would. That's not a disorder. It's a trait. But when that trait is operating in a body that also has MCAS, or autonomic dysregulation, or a perimenopausal hormonal shift removing its buffers, the load becomes clinical rather than constitutional. The difference between those presentations matters enormously for what actually helps.

The world isn't going to turn its volume down. But understanding why it's loud for you specifically — mechanistically, not metaphorically — is the beginning of a more useful conversation than the one that starts and ends with "you're too sensitive."